Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: A post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial

Clinical Therapeutics

Volumn 30, Issue 12, 2008, Pages 2354-2365

  Lewin, Andrew J ^a   Weir, Matthew R ^b  

^a NATIONAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

antihypertensive efficacy; diabetes; hypertension; irbesartan hydrochlorothiazide; obesity

Indexed keywords

HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SPRAIN; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

AGED; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BODY MASS INDEX; BODY WEIGHT; CLUSTER ANALYSIS; DIABETES MELLITUS, TYPE 2; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPOTENSION; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 58249132657     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.018     Document Type: Article

References (30)

1. Sowers J.R. Obesity as a cardiovascular risk factor. Am J Med. 115 Suppl 8A (2003) 37S-41S
2. Haffner S., and Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 108 (2003) 1541-1545
3. Chan J.M., Rimm E.B., Colditz G.A., et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 17 (1994) 961-969
4. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
5. Stein C.J., and Colditz G.A. The epidemic of obesity. J Clin Endocrinol Metab. 89 (2004) 2522-2525
6. Bramlage P., Pittrow D., Wittchen H.U., et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 17 (2004) 904-910
7. Rahmouni K., Correia M.L., Haynes W.G., and Mark A.L. Obesity-associated hypertension: New insights into mechanisms. Hypertension. 45 (2005) 9-14
8. Chobanian A.V., Bakris G.L., Black H.R., et al., for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290:197]. JAMA 289 (2003) 2560-2572
9. Mancia G., De Backer G., Dominiczak A., et al., for the Management of Arterial Hypertension of the European Society of Hypertension, the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [published correction appears in J Hypertens. 2007;25:1749]. J Hypertens 25 (2007) 1105-1187
10. The American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 27 Suppl 1 (2004) S15-S35
11. Neutel J.M., Saunders E., Bakris G.L., et al., for the INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: The INCLUSIVE trial. J Clin Hypertens (Greenwich). 7 (2005) 578-586
12. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 106 (2002) 3143-3421
13. In: Fleiss J.L. (Ed). Statistical Methods for Rates and Proportions. 2nd ed. (1981), Wiley, New York, NY
14. Cushman W.C., Neutel J.M., Saunders E., et al. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled on monotherapy. Am J Geriatr Cardiol. 17 (2008) 27-36
15. Sowers J.R., Neutel J.M., Saunders E., et al., for the INCLUSIVE Investigators. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 8 (2006) 470-480
16. Berlowitz D.R., Ash A.S., Hickey E.C., et al. Hypertension management in patients with diabetes: The need for more aggressive therapy. Diabetes Care. 26 (2003) 355-359
17. Lindholm L.H., Ibsen H., Dahlöf B., et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 359 (2002) 1004-1010
18. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196]. JAMA 288 (2002) 2981-2997
19. Hansson L., Zanchetti A., Carruthers S.G., et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 351 (1998) 1755-1762
20. Julius S., Kjeldsen S.E., Weber M., et al., for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 363 (2004) 2022-2031
21. McFarlane S.I., Castro J., Kaur J., et al. Control of blood pressure and other cardiovascular risk factors at different practice settings: Outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich). 7 (2005) 73-80
22. Parving H.H., Lehnert H., Bröchner-Mortensen J., et al., for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 345 (2001) 870-878
23. Kochar M., Guthrie R., Triscari J., et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 12 (1999) 797-805
24. Benedict C.R. Safe and effective management of hypertension with fixed-dose combination therapy: Focus on losartan plus hydrochlorothiazide. Int J Clin Pract. 54 (2000) 48-54
25. Chrysant S.G. Fixed combination therapy of hypertension: Focus on valsartan/hydrochlorothiazide combination (Diovan/HCT). Expert Rev Cardiovasc Ther. 1 (2003) 335-343
26. Croom K.F., Curran M.P., Goa K.L., and Perry C.M. Irbesartan: A review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 64 (2004) 999-1028
27. Chrysant S.G., and Chrysant G.S. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother. 5 (2004) 657-667
28. Ofili E.O., Ferdinand K.C., Saunders E., et al. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 98 (2006) 618-626
29. Neutel J.M., Franklin S.S., Oparil S., et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich). 8 (2006) 850-857
30. Neutel J.M., Franklin S.S., Lapuerta P., et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens. 22 (2008) 266-274